|
- Use Ianalumab On Top Of Standard-of-care Therapy In . . . - UCI Health
This clinical trial, a Phase 3 study, evaluates the efficacy, safety and tolerability of ianalumab with standard therapy in systemic lupus erythematosus patients
- Phase 3 Trial to Evaluate Ianalumab in Patients with . . . - UCI Health
Participation in UCI clinical research studies help us gain important data and knowledge that may lead to improved treatment options for people with similar conditions to you in the future There are no alternative procedures available
- ClinicalTrials. gov
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s c ) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE)
- UC Irvine Lupus Clinical Trials for 2025 — Orange County, CA
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s c ) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE)
- UC Irvine Lupus Trial: Ianalumab on Top of Standard-of-care Therapy in . . .
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s c ) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE)
- Phase 3 Trial to Evaluate Ianalumab in Patients with Active Lupus . . .
A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial To Evaluate The Efficacy, Safety, And Tolerability Of Ianalumab On Top Of Standard-of-care Therapy In Participants With Active Lupus Nephritis
- UC Irvine Lupus Trial: Ianalumab Versus Placebo, Combination With SoC . . .
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s c ) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
- Use Ianalumab On Top Of Standard-of-care Therapy In Patients With . . .
A randomized, double-blind, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2)
|
|
|